SPShabana F. Pasha

Shabana F. Pasha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shabana F. Pasha has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ACG Workforce of the Future Task Force: The Anesthetizing Task Force Report

    by Dayna Early, Stephen T. Amann, Brooks Cash, Daniel Pambianco, Shabana F. Pasha, Sheetal Sharma, Amy Stratton, John Vargo

    Was not provided for this article.

  • Open Access

    Novel Genetic Risk Variants and Clinical Predictors Associated With Primary Sclerosing Cholangitis in Patients With Ulcerative Colitis

    by Ming-Hsi Wang, Jessica J. Friton, Nancy Rebert, Kelly Monroe, Billy D. Nix, Claudio Fiocchi, Laura E. Raffals, Jonathan A. Leighton, Shabana F. Pasha, Michael F. Picco, et al.

    INTRODUCTION: Patients with ulcerative colitis (UC) who are likely to have primary sclerosing cholangitis (PSC) should be identified because PSC can influence UC clinical behavior and outcomes.The aim of this study was to establish a model incorporating clinical and genetic risk predictors that identifies patients with UC at risk of developing PSC. METHODS: We conducted a retrospective case-control study. Inflammatory bowel disease cohorts from multiple institutions were used as discovery and replicate datasets. Quality control criteria, including minor allele frequency, call rates, Hardy-Weinberg equilibrium, cryptic relatedness, and population stratification (through principal components), were used. Discriminative accuracy was evaluated with area under the receiver operating characteristic curve. RESULTS: Fifty-seven of 581 patients (9.8%) with UC had PSC. Multivariate analysis showed that patients with UC-PSC had more extensive disease (odds ratio [OR], 5.42; P = 1.57E-04), younger diagnosis age (younger than 20 years; OR, 2.22; P = 0.02), and less smoking (OR, 0.42; P = 0.02) than those with UC. After linkage disequilibrium pruning and multivariate analyses, 3 SNPs (rs3131621 at 6p21.33; rs9275596 and rs11244 at 6p21.32) at the HLA region were found associated with a 2- to 3-fold increased risk of PSC. Our model demonstrated good discriminatory power (area under the receiver operating characteristic curve, 88%). DISCUSSION: Three variants in HLA (6p21.3) region significantly distinguished patients with UC-PSC from patients with UC alone. Once further validated in an independent large cohort, our model could be used to identify patients with UC at risk of PSC, and it could also help guide disease management.


  • Gastric ischemia and portal vein thrombosis in a COVID-19-infected patient

    by See-Wei Low, Karen L. Swanson, Josiah D. McCain, Ayan Sen, Akira Kawashima, Shabana F. Pasha

    A 51-year-old man admitted with acute respiratory failure from a SARS-CoV-2 infection had large volume of bloody output via orogastric tube following initiation of heparin for a lower extremity deep vein thrombosis. Esophagogastroduodenoscopy revealed diffuse and severe mucosal ischemia involving the gastric fundus ([Fig. 1]), greater curvature, and posterior wall of the gastric body and antrum ([Fig. 2]) ([Video 1]). The anterior gastric wall and duodenum appeared normal. Computed tomography (CT) angiogram of the abdomen revealed gastric pneumatosis ([Fig. 3]), a non-occlusive thrombus in the right and left portal veins, and portal venous gas ([Fig. 4]). The small bowel and colon appeared normal. In addition to management of the underlying COVID infection and respiratory complications, management included nasogastric decompression and intravenous heparin. A repeat abdominal CT 1 week later showed resolution of the intramural gastric and portal venous gas, and no residual portal vein thrombosis ([Fig. 5]). Video 1 Esophagogastroduodenoscopy findings of gastric mucosal ischemia with normal duodenum in the setting of COVID-19 infection. Gastrointestinal tract involvement, ranging from minor symptoms to small bowel ischemia, has been reported with the SARS-CoV-2 virus, which may be due to a high surface expression of angiotensin-converting enzyme 2 (ACE2) receptors on gastric cells and enterocytes [1] [2]. The underlying mechanism of small bowel ischemia is not known but might result from direct viral infiltration via ACE2 receptors on enterocytes and endothelial cells, complement-mediated small vessel thrombosis, non-occlusive mesenteric ischemia, or systemic coagulopathy [3] [4]. Gastric ischemia is a rare condition that results from vascular insufficiency due to local or systemic disorders and is associated with poor clinical outcomes if not recognized and treated early [5]. Our patient had gastric ischemia and portal vein thrombosis in the setting of a COVID-19 infection in the absence of other thromboembolic risk factors. Based on a review of the literature, we found no reported cases of COVID-19-associated gastric ischemia. A high index of suspicion may result in early recognition of this complication and treatment with anticoagulation. Endoscopy_UCTN_Code_CCL_1AB_2AC_3AZ Publication Date: 02 September 2020 (online) © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Capsule Retention in Crohn’s Disease: A Meta-analysis

    by Shabana F Pasha, Marco Pennazio, Emanuele Rondonotti, Douglas Wolf, Matthew R Buras, Jörg G Albert, Stanley A Cohen, Jose Cotter, Geert D’haens, Rami Eliakim, et al.

    The main factor that limits wider utilization of capsule endoscopy (CE) in Crohn’s disease (CD) is the potential risk of retention. The aim of this systematic review was to evaluate capsule retention rates in adult and pediatric CD and determine if retention risk is reduced in established CD (ECD) with patency capsule (PC) or magnetic resonance/computed tomography (MR/CT) enterography. Studies of CD patients undergoing CE that reported retention were identified. Pooled estimates for retention rates and relative risk in ECD to suspected CD (SCD) were calculated. All hypothesis tests were 2-sided; statistical significance was set at a P value of <0.05. In the overall CD cohort, retention rates were 3.32% (95% confidence interval [CI], 2.62%–4.2%): 4.63% (95% CI, 3.42%–6.25%) and 2.35% (95% CI, 1.31%–4.19%) in ECD and SCD, respectively. Retention rates were 3.49% (95% CI, 2.73%–4.46%) and 1.64% (95% CI, 0.68%–3.89%) in adult and pediatric CD, respectively. Retention risk in adult ECD was 3.4 times higher than SCD, but there was no difference in retention risk in pediatric ECD compared with SCD. Retention rates in ECD were decreased after patency capsule (2.88%; 95% CI, 1.74%–4.74%) and MR/CT enterography (2.32%; 95% CI, 0.87%–6.03%). In comparison with older literature, this meta-analysis demonstrates lower CE retention rates in SCD and ECD. Retention rates in pediatric CD were lower than in adult CD. Retention rates in adult ECD were higher than SCD, but there were no differences between pediatric ECD and SCD. Retention rates in ECD were lower after negative PC or MR/CT enterography.


  • Applications of Colon Capsule Endoscopy

    by Shabana F. Pasha

    This is a review of colon capsule endoscopy (CCE) with a focus on its recent developments, technological improvements, and current and potential future indications.


    • 1 February 2017
      • Vol. 13  (2) , 88-93

    Evidence-Based Guide on Capsule Endoscopy for Small Bowel Bleeding.

    by Shabana F Pasha, Jonathan A Leighton

    Capsule endoscopy is the diagnostic test of choice for the evaluation of overt and occult small bowel bleeding. Its yield is higher in patients presenting with overt bleeding. The yield is also improved if the capsule is performed soon after the presentation of bleeding. Capsule endoscopy has a complementary role with cross-sectional imaging to triage patients for appropriate management, including deep enteroscopy, surgery, or, if negative, conservative management. Although capsule endoscopy is useful to detect vascular and inflammatory lesions, it appears to have a significant miss rate for solitary small bowel lesions, including tumors. The main adverse event is capsule retention in patients with underlying small bowel obstruction.


  • Detection of suspected small bowel bleeding: challenges and controversies

    by Shabana F. Pasha, Jonathan A. Leighton

    Introduction: Detection of small bowel (SB) bleeding remains a challenge to gastroenterologists, with a dearth of standardized recommendations regarding evaluation and management. Areas covered: A recursive literature search was performed using PubMed, Cochrane and Medline databases for original and review articles on SB and obscure gastrointestinal bleeding (OGIB). Based upon the available literature, this review outlines the main challenges and controversies, and provides a practical and cost-effective approach towards SB bleeding. Expert commentary: SB bleeding is suspected in patients with persistent or recurrent bleeding after negative bidirectional endoscopy, and unexplained iron deficiency anemia. Selection of test(s) should be individualized based upon patient presentation and suspicion for type of underlying lesion. Endoscopic or radiologic evaluation and treatment is the mainstay in the majority of patients, while pharmacologic agents may have a role in patients with refractory bleeding, and those unable to undergo evaluation.


  • Alternatives to Incomplete Colonoscopy

    by Nicolas A. Villa, Rahul Pannala, Shabana F. Pasha, Jonathan A. Leighton

    A thorough and complete colonoscopy is critically important in preventing colorectal cancer. Factors associated with difficult and incomplete colonoscopy include a poor bowel preparation, severe diverticulosis, redundant colon, looping, adhesions, young and female patients, patient discomfort, and the expertise of the endoscopist. For difficult colonoscopy, focusing on bowel preparation techniques, appropriate sedation and adjunct techniques such as water immersion, abdominal pressure techniques, and patient positioning can overcome many of these challenges. Occasionally, these fail and other alternatives to incomplete colonoscopy have to be considered. If patients have low risk of polyps, then noninvasive imaging options such as computed tomography (CT) or magnetic resonance (MR) colonography can be considered. Novel applications such as Colon Capsule™ and Check-Cap are also emerging. In patients in whom a clinically significant lesion is noted on a noninvasive imaging test or if they are at a higher risk of having polyps, balloon-assisted colonoscopy can be performed with either a single- or double-balloon enteroscope or colonoscope. The application of these techniques enables complete colonoscopic examination in the vast majority of patients.


  • Endoscopic Techniques for Small Bowel Imaging

    by Shabana F. Pasha, Jonathan A. Leighton


  • Comparison of Single- Versus Double-Balloon Assisted-Colonoscopy for Colon Examination After Previous Incomplete Standard Colonoscopy

    by Ivana Dzeletovic, M. Edwyn Harrison, Shabana F. Pasha, Michael D. Crowell, G. Anton Decker, Suryakanth R. Gurudu, Jonathan A. Leighton

    Colonoscopy fails to achieve cecal intubation in 5–10 % of cases. Many of these cases can be completed using balloon-assisted colonoscopy, either with the single-balloon colonoscopy (SBC) or the double-balloon colonoscopy (DBC) techniques. To compare the completion rates of SBC and DBC in patients with previous incomplete conventional colonoscopy. Between August 2009 and July 2011 either SBC or DBC was performed in 53 patients in whom previous conventional colonoscopy did not achieve cecal intubation. The medical records of these 53 patients were reviewed retrospectively for details regarding (1) indication for the initial colonoscopy, (2) patient characteristics, (3) data from the initial colonoscopy, and (4) details on both SBC and DBC. SBC was successful in intubating the cecum in 100 % (26/26) of patients and DBC was successful in 93 % (25/27) of patients. The median (range) time to reach the cecum was 17 (9–43) min in the SBC group and 20 (7–58) min in the DBC group (P = 0.37). The presence of polyps was an entirely new finding in 35 % (9/26) of patients in the SBC group and 30 % (8/27) of patients in DBC group. Therapeutics were performed in 73 % (19/26) of patients in SBC group and 67 % (18/27) of patients in DBC group. For patients with incomplete conventional colonoscopy, SBC and DBC offer high cecal intubation rates as well as detection of additional polyps and therapeutic capability. Either SBC or DBC can be considered after incomplete conventional colonoscopy.